Annual Reports

FY18 Annual Report

The Company’s focus during the year was the development of DMX-200 for kidney disease. The compelling data from the Dimerix Phase 2a clinical trial were used to shape the next stage of clinical trial development looking at two Phase 2 clinical studies in the areas of kidney disease: DMX-200 for Diabetic Kidney Disease; and DMX-200 for Focal Segmental Glomerulosclerosis (FSGS).

Download Opens in new window Opens in new window

Join the Dimerix mailing list to receive the latest company news.

Join now